SPD 2025: Key Takeaways & Highlights

Pediatric Dermatology Advances: Key Takeaways from the 2025 SPD Annual Meeting

New research and expert insights presented at the Society for Pediatric Dermatology (SPD) conference in Seattle, Washington, are poised to reshape the landscape of care for young patients facing dermatological challenges.

The 50th annual meeting of the SPD delivered significant updates on therapies for atopic dermatitis and highlighted critical conversations surrounding access and equity in pediatric dermatology. Experts emphasized the need for increased awareness, improved diagnostic accuracy, and innovative approaches to treatment, particularly for underrepresented communities.

Ruxolitinib Cream Demonstrates Long-Term Safety in Atopic Dermatitis

A comprehensive analysis of data from eight clinical trials has reinforced the favorable safety profile of ruxolitinib cream for children and adolescents with atopic dermatitis. Researchers found that adverse events were uncommon or absent among pediatric patients participating in the trials. This finding underscores the potential of Janus kinase (JAK) inhibitors as a therapeutic option for vulnerable young patients struggling with this chronic inflammatory skin condition. The data provides reassurance for clinicians considering this treatment modality.

Addressing Disparities in Pediatric Dermatology Access

Expanding access to specialized dermatological care for children remains a significant hurdle, particularly in rural and underserved communities. According to a medical student at the University of Colorado School of Medicine, a key challenge is simply raising awareness of pediatric dermatology as a subspecialty within these populations, especially among Hispanic and Latino communities. Furthermore, she noted the critical need for greater representation and exposure among physicians to a diverse range of skin colors to improve diagnostic accuracy and reduce disparities in care.

Recognizing and Treating Underdiagnosed Pediatric Skin Conditions

A rising researcher highlighted the challenges associated with diagnosing and treating less common pediatric skin conditions, such as segmental vitiligo. Compliance with treatment regimens can be difficult in younger children, who may resist the need for twice-daily applications. Moreover, accurate diagnosis is often complicated by the fact that many skin conditions present differently on skin of color compared to White children, leading to potential misdiagnosis or delayed treatment.

Early Diagnosis of Hidradenitis Suppurativa Crucial for Pediatric Patients

Early and accurate diagnosis of hidradenitis suppurativa in pediatric patients is paramount, yet often delayed. Experts emphasize that the initial symptoms of this chronic inflammatory condition can easily be mistaken for acne, folliculitis, or abscesses. A new educational module is being developed to increase awareness of hidradenitis suppurativa and reduce the stigma associated with the condition, aiming to facilitate earlier intervention and improved outcomes.

Dupilumab and IgE Levels in Pediatric Atopic Dermatitis: Potential Implications for Concurrent Immune Disorders

Research presented at the SPD meeting suggests that dupilumab, a biologic medication used to treat atopic dermatitis, significantly reduces levels of immunoglobulin E (IgE) in pediatric patients. While IgE is not considered the primary driver of atopic dermatitis, researchers believe this reduction may offer benefits for patients with concurrent or future type 2 immune disorders, such as asthma and food allergy. This finding opens new avenues for exploring the broader immunological impact of dupilumab in pediatric populations.

The insights shared at the SPD 2025 conference underscore the ongoing commitment to advancing the field of pediatric dermatology and improving the lives of young patients facing a wide range of skin conditions.